Identification of the optimal cetuximab concentration that is effective against oral squamous cell carcinoma in collagen gel droplet embedded culture drug sensitivity testing

Sakuma,Kaname; Hanyu,Shintaro; Takahashi,Haruka; Tanaka,Akira

doi:10.3892/mco.2019.1953

Identification of the optimal cetuximab concentration that is effective against oral squamous cell carcinoma in collagen gel droplet embedded culture drug sensitivity testing

Authors:
- Kaname Sakuma
- Shintaro Hanyu
- Haruka Takahashi
- Akira Tanaka
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, The Nippon Dental University, Niigata Hospital, Niigata 951‑8580, Japan, Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Niigata 951‑8580, Japan
Published online on: November 20, 2019 https://doi.org/10.3892/mco.2019.1953
Pages: 51-56

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anticancer drug sensitivity testing using the collagen gel droplet embedded culture drug sensitivity test (CD‑DST) on oral squamous cell carcinoma (OSCC) samples beginning from 2010 has been conducted. The present study investigated the effect of adding cetuximab (Erbitux®), a molecularly targeted drug, on anticancer drug activity against clinical OSCC specimens. A total of 25 specimens were obtained from 25 patients with OSCC between October 2013 and December 2017. The present study conducted anticancer drug sensitivity testing for cisplatin (CDDP), 5‑fluorouracil (5‑FU), cetuximab, three‑drug combination, single agent and multi drug combinations, and cetuximab addition to the aforementioned regimens using CD‑DST. In addition, the optimum concentration of each drug was evaluated. The overall evaluation success rate of the CD‑DST method for OSCC specimens was 84.0% (21 of 25 cases); sensitivity to anticancer drugs and cetuximab could be evaluated. The in vitro efficacy rate of a cetuximab single agent and CDDP + 5‑FU (PF) at a cut-off value of 50% was similar to the known clinical response rate. However, at a cut-off value of 50%, the in vitro efficacy of PF + cetuximab was calculated to be 40%, which was higher than the clinical response rate. The CD‑DST method could be used to evaluate cetuximab, a molecularly targeted drug. Furthermore, its additive effect on conventional chemotherapy could be evaluated. The CD‑DST method is suitable for evaluating and selecting chemotherapy regimens, including molecularly targeted drugs. Future studies are required to generate and evaluate relevant clinical data.

View Figures

View References

1	Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
2	Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
3	Rivera F, García-Castaño A, Vega N, Vega-Villegas ME and Gutiérrez-Sanz L: Cetuximab in metastatic or recurrent head and neck cancer: The EXTREME trial. Expert Rev Anticancer Ther. 9:1421–1428. 2009. View Article : Google Scholar : PubMed/NCBI
4	Yoshino T, Hasegawa Y, Takahashi S, Monden N, Homma A, Okami K, Onozawa Y, Fujii M, Taguchi T, de Blas B, et al: Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of a phase II trial. Jpn J Clin Oncol. 43:524–531. 2013. View Article : Google Scholar : PubMed/NCBI
5	Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, Yasutomi M, et al: An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol. 11:449–455. 1997.PubMed/NCBI
6	Kobayashi H: Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res. 161:48–61. 2003. View Article : Google Scholar : PubMed/NCBI
7	Shintani S, Hino S, Nakashiro K and Hamakawa H: Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions. Gan To Kagaku Ryoho. 33:357–360. 2006.(In Japanese). PubMed/NCBI
8	Kobayashi H, Tanisaka K, Kondo N, Mito Y, Koezuka M, Yokouchi H, Higashiyama M, Kodama K, Doi O and Yamada M: Development of new in vitro chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness. Gan To Kagaku Ryoho. 22:1933–1939. 1995.(In Japanese). PubMed/NCBI
9	Sakuma K, Tanaka A and Mataga I: Collagen gel droplet- embedded culture drug sensitivity testing in squamous cell carcinoma cell lines derived from human oral cancers: Optimal contact concentrations of cisplatin and fluorouracil. Oncol Lett. 12:4643–4650. 2016. View Article : Google Scholar : PubMed/NCBI
10	Ryuki T, Sakuma K and Tanaka A: Optimal cetuximab contact concentration using a collagen gel droplet-embedded culture drug chemosensitivity test in human oral squamous carcinoma cell lines. Chemotherapy. 7:253–260. 2018.
11	Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H and Ohtsu A: Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. Jpn J Clin Oncol. 39:225–230. 2009. View Article : Google Scholar : PubMed/NCBI
12	Saijo N: Molecular target therapy in cancer. Nihon Rinsho. 68:1779–1786. 2010.(In Japanese). PubMed/NCBI
13	Saijo N: Molecular targeted therapy for lung cancer, recent topics. J Lung Cancer. 7:1–8. 2008. View Article : Google Scholar
14	Lurje G and Lenz HJ: EGFR signaling and drug discovery. Oncology. 77:400–410. 2009. View Article : Google Scholar : PubMed/NCBI
15	Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1935–1940. 1999.PubMed/NCBI
16	Araki Y, Isomoto H, Matsumoto A, Kaibara A, Yasunaga M, Hayashi K, Yatsugi H and Yamauchi K: An in vitro chemosensitivity test for colorectal cancer using collagen-gel droplet embedded cultures. Kurume Med J. 46:163–166. 1999. View Article : Google Scholar : PubMed/NCBI
17	Kawamura M, Inoue Y, Oyama T and Kobayashi H: Chemosensitivity test for unresectable non-small cell lung cancer. Nihon Geka Gakkai Zasshi. 103:229–232. 2002.(In Japanese). PubMed/NCBI
18	Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H and Noguchi S: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer. 98:450–455. 2002. View Article : Google Scholar : PubMed/NCBI
19	Sakuma K, Tamura R, Hanyu S, Takahashi H, Sato H, Oneyama T, Yamaguchi A and Tanaka A: Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intraarterial infusion chemoradiotherapy in oral squamous cell carcinoma. Mol Clin Oncol. 7:1021–1026. 2017.PubMed/NCBI
20	Sakuma K, Tamura R, Noda N, Mizutani M, Yamaguchi A and Tanaka A: Collagen gel droplet-embedded culture drug sensitivity testing in hard palate cancer-predicted antitumor efficacy of cetuximab: A case report. Mol Clin Oncol. 7:637–641. 2017. View Article : Google Scholar : PubMed/NCBI
21	Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T and Nishio K: Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98:1275–1280. 2007. View Article : Google Scholar : PubMed/NCBI